This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
How Should You Play UnitedHealth Stock Going Into Q1 Earnings?
by Kaibalya Pravo Dey
UNH's first-quarter earnings are likely to have benefited from growing premiums and service revenues.
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EUSA
Humana Gains on Strong Membership Base and Sound Cash Reserves
by Zacks Equity Research
HUM benefits from a cost-effective health plan suite, continued expansion endeavors and a strong 2025 business outlook.
Molina Healthcare Expands Presence With Illinois D-SNP Contract Win
by Zacks Equity Research
MOH secures a key Illinois contract, strengthening its foothold in the dual-eligible market.
Molina (MOH) Up 13.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Molina Healthcare Q4 Earnings Miss Estimates on Growing Medical Costs
by Zacks Equity Research
MOH expects total membership to be at 5.9 million by 2025-end.
Compared to Estimates, Molina (MOH) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Molina (MOH) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Molina (MOH) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of -13.08% and 0.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Molina Healthcare to Report Q4 Earnings: What Do the Estimates Say?
by Zacks Equity Research
MOH's fourth-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
What Analyst Projections for Key Metrics Reveal About Molina (MOH) Q4 Earnings
by Zacks Equity Research
Get a deeper insight into the potential performance of Molina (MOH) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Centene (CNC) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of 63.27% and 4.75%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Molina (MOH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Elevance Health Q4 Countdown: Smart Move to Buy or Stick With Hold?
by Zacks Equity Research
ELV's fourth-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
UnitedHealth Stock Q4 Earnings Preview: Buy Now or Wait for Results?
by Kaibalya Pravo Dey
UNH's fourth-quarter earnings are likely to have benefited from growing premiums and service revenues.
Will Molina (MOH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Molina (MOH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Investors Should Retain Molina Healthcare Stock for Now
by Zacks Equity Research
MOH remains well-poised for growth, attributable to improved premium revenues, buyouts and an aging U.S. population.
Molina (MOH) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Molina (MOH) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cigna (CI) Soars 6.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Cigna (CI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Is Molina (MOH) Down 8.5% Since Last Earnings Report?
by Zacks Equity Research
Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
JYNT's Q3 Earnings Meet Estimates Amid Higher Costs, Shares Dip 3%
by Zacks Equity Research
The Joint's Q3 results reflect higher general and administrative costs. Revenues benefit from strong royalty fees and advertising revenues.
Elevance Health Declines 20% in 3 Months: Time to Sell the Stock?
by Debasmita Chatterjee
ELV encounters headwinds such as higher benefit costs, an increased debt level and member attrition in the Medicaid business, which raise concerns among investors.
Encompass Health Q3 Earnings Beat on Higher Discharges, Stock Up 6.3%
by Zacks Equity Research
EHC's third-quarter results benefit from improved patient discharges. Higher operating expenses act as a partial offset.
Ensign Group Q3 Earnings Beat on Patient Days, Stock Up 4.1%
by Zacks Equity Research
ENSG's strong third-quarter earnings benefit from improved occupancy and skilled mix days. Higher expenses partially offset the positives.
Cigna Q3 Earnings Beat on Client Wins & Specialty Business Strength
by Zacks Equity Research
CI's strong third-quarter results benefit from a strong Evernorth Health Services segment. Higher expenses partially offset the positives.